Nov 20, 2017
NanoViricides Files Quarterly Report for Period Ending September 30, 2017
Nov 07, 2017
Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Oct 26, 2017
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
Oct 25, 2017
Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles
Oct 25, 2017
CDC's Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Oct 20, 2017
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Oct 20, 2017
FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant
Oct 17, 2017
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
Sep 29, 2017
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials
Sep 13, 2017
FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
Aug 02, 2017
Uveitis Therapeutics Pipeline Analysis, 2017 - 33 Active Drug Candidates in Different Stages of Development
Jun 26, 2017
NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology
Jun 21, 2017
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting
Jun 13, 2017
NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City
Jun 06, 2017
NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies
Jun 05, 2017
Demand for Asphalt Shingles to Grow 5.6% Annually Through 2021